Cornelissen E A, Monnens L A
Academisch Ziekenhuis, afd. Kindergeneeskunde, Nijmegen.
Ned Tijdschr Geneeskd. 1993 Oct 23;137(43):2205-8.
To establish recommendations for prevention of vitamin K deficiency in healthy breastfed infants.
Prospective clinical trials of different methods of vitamin K prophylaxis.
Study of vitamin K1 and proteins induced by vitamin K absence (PIVKA)-II concentrations, and some coagulation factors at the ages of 2, 4, 8 and 12 weeks in healthy breastfed infants with either once 1 mg vitamin K1 orally (n = 165) or intramuscularly (n = 166), or weekly 1 mg orally (n = 48), or daily 25 micrograms orally (n = 58).
Despite significantly higher vitamin K1 plasma concentrations after intramuscular administration, there was no difference in activities of coagulation factors VII and X, and PIVKA-II concentrations between oral and intramuscular administration. The two single administrations of 1 mg could not prevent the appearance of PIVKA-II after the age of 1 month. When vitamin K was administered as 1 mg per week or 0.025 mg per day, significantly higher concentrations of vitamin K1 were found and no PIVKA-II was detectable.
A single administration of 1 mg vitamin K1 orally or intramuscularly may not afford complete protection against late vitamin K deficiency in healthy breastfed infants. A regimen of 1 mg per week or 25 micrograms vitamin K1 per day proved to be effective in prevention of vitamin K deficiency and the latter is recommended for breastfed infants during the first three months of life.
制定健康母乳喂养婴儿维生素K缺乏症的预防建议。
不同维生素K预防方法的前瞻性临床试验。
对健康母乳喂养婴儿在2、4、8和12周龄时的维生素K1及维生素K缺乏诱导蛋白(PIVKA)-II浓度以及一些凝血因子进行研究,这些婴儿分别接受一次口服1mg维生素K1(n = 165)、一次肌肉注射1mg维生素K1(n = 166)、每周口服1mg(n = 48)或每日口服25μg(n = 58)。
尽管肌肉注射后维生素K1血浆浓度显著更高,但口服和肌肉注射在凝血因子VII和X的活性以及PIVKA-II浓度方面并无差异。两次单次给予1mg并不能预防1月龄后PIVKA-II的出现。当维生素K按每周1mg或每日0.025mg给药时,发现维生素K1浓度显著更高且未检测到PIVKA-II。
单次口服或肌肉注射1mg维生素K1可能无法为健康母乳喂养婴儿提供针对晚期维生素K缺乏症的完全保护。每周1mg或每日25μg维生素K1的给药方案被证明对预防维生素K缺乏有效,建议在出生后的前三个月对母乳喂养婴儿采用后者的方案。